Recent developments

at Tullis and our portfolio companies

News

Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.

May

26

electroCore, Inc. Announces Departure of JP Errico from the Board of Directors

ROCKAWAY, N.J., May 26, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and...

3

electroCore Announces First Quarter 2023 Financial Results

Record first quarter 2023 net sales of $2.8 million, approximately 46% over first quarter 2022 ROCKAWAY, N.J., May 03,...

24

Study Presented at 75th Annual Meeting of the American Academy of Neurology Demonstrates that gammaCore (nVNS) Can Accelerate Foreign Language Learning

Clinical trial (n=36) shows the ability of gammaCore (nVNS) to significantly improve the recall...

17

electroCore Provides Select First Quarter 2023 Financial Guidance

ROCKAWAY, N.J., April 17, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial-stage...

12

electroCore Expands Intellectual Patent Portfolio for nVNS Technology

electroCore Granted Three New U.S. Patents ROCKAWAY, N.J., April 12, 2023 (GLOBE NEWSWIRE) — electroCore, Inc....

6

electroCore, Inc. Announces Product Registration in Indonesia, Malaysia and South Africa

ROCKAWAY, N.J., April 06, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage...

4

electroCore, Inc. Announces gammaCore Non-Invasive Vagus Nerve Stimulator Available Through the Carrick Institute

ROCKAWAY, N.J., April 04, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage...

23

electroCore Reports Results of Pre-Clinical Trial in a Model of Traumatic Brain Injury

Pre-clinical trial demonstrates the ability of nVNS to decrease the amount of brain injury,...

21

electroCore’s Truvaga Users Reported Improved Stress, Anxiety, Sleep, Energy and Mood in Recent Focus Group Study

ROCKAWAY, N.J., March 21, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage...

8

electroCore Announces Fourth Quarter and Full Year 2022 Financial Results

Record full year 2022 net sales of $8.6 million increased 58% over $5.5 million for...

21

electroCore, Inc. Announces Exclusive Distribution Agreement with Byond Healthcare Pty Ltd, South Africa

ROCKAWAY, N.J., Feb. 21, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage...

16

electroCore Expands Intellectual Patent Portfolio for nVNS Technology

ROCKAWAY, N.J., Feb. 16, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine...

Recent developments

News

May

26

electroCore, Inc. Announces Departure of JP Errico from the Board of Directors

May

3

electroCore Announces First Quarter 2023 Financial Results

April

24

Study Presented at 75th Annual Meeting of the American Academy of Neurology Demonstrates that gammaCore (nVNS) Can Accelerate Foreign Language Learning

April

17

electroCore Provides Select First Quarter 2023 Financial Guidance

April

12

electroCore Expands Intellectual Patent Portfolio for nVNS Technology

April

6

electroCore, Inc. Announces Product Registration in Indonesia, Malaysia and South Africa

April

4

electroCore, Inc. Announces gammaCore Non-Invasive Vagus Nerve Stimulator Available Through the Carrick Institute

March

23

electroCore Reports Results of Pre-Clinical Trial in a Model of Traumatic Brain Injury

March

21

electroCore’s Truvaga Users Reported Improved Stress, Anxiety, Sleep, Energy and Mood in Recent Focus Group Study

March

8

electroCore Announces Fourth Quarter and Full Year 2022 Financial Results

February

21

electroCore, Inc. Announces Exclusive Distribution Agreement with Byond Healthcare Pty Ltd, South Africa

February

16

electroCore Expands Intellectual Patent Portfolio for nVNS Technology